OHMX.bio partners in BRECISE project to revolutionize prostate and bladder cancer treatment assessment

OHMX.bio is proud to announce its participation in the BRECISE project, a groundbreaking five-year research initiative co-funded by the Innovative Health Initiative (IHI) under the Horizon Europe program. With its official kick-off in Madrid on March 20-21, 2025, BRECISE aims to accelerate the clinical validation and implementation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) biomarkers for prostate and bladder cancers.

Transforming Cancer Care through Innovation

Prostate and bladder cancers affect millions worldwide, yet the clinical adoption of validated biomarkers for predicting treatment responses and disease progression remains limited. BRECISE seeks to address this gap by integrating advanced technologies, including NGS, AI, and ex vivo drug testing, to refine personalized treatment strategies. This comprehensive approach promises to enhance diagnostic accuracy, predict therapeutic outcomes, and monitor disease progression more effectively.

OHMX.bio's role in BRECISE

As a key in the BRECISE consortium, OHMX.bio brings its expertise in clinical sequencing solutions to the forefront of this initiative. Our contributions will focus on:

Advanced sequencing technologies

Utilizing state-of-the-art platforms to generate high-quality genomic data essential for biomarker discovery and validation.

Integrated bioinformatics

Developing robust analytical pipelines to interpret complex genomic information, facilitating the identification of clinically relevant biomarkers.

Quality and compliance

Ensuring that all processes adhere to the highest quality standards and regulatory requirements, including ISO certifications and Good Clinical Laboratory Practice (GCLP) guidelines.

Collaborative effort for a common goal

Led by Philips and the South East Technological University, the BRECISE consortium comprises 12 private, 15 public, and 3 associate partners. This multidisciplinary collaboration unites academic institutions, research centers, healthcare providers, industry leaders, and patient organizations, all dedicated to translating scientific discoveries into tangible clinical benefits.

Looking ahead

The launch of BRECISE marks a significant milestone in the pursuit of precision oncology. By fostering the development and implementation of AI-driven biomarkers, the project aims to integrate personalized medicine into routine clinical practice, ultimately improving patient outcomes and optimizing healthcare resources.

For more information about the BRECISE project, please visit https://brecise.eu/.

Note: This blog post is based on the official BRECISE project press releases: https://euapm.eu/press-release-brecise-holds-first-face-to-face-kick-off-meeting-in-madrid/ https://www.ihi.europa.eu/projects-results/project-factsheets/brecise